Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 12, 2019
- Accepted in final form March 15, 2020
- First Published May 28, 2020.
Author Disclosures
- Jiraporn Jitprapaikulsan, MD,
- James P. Fryer, MS,
- Masoud Majed, MD,
- Carin Y. Smith, BS,
- Sarah M. Jenkins, MS,
- Philippe Cabre, MD,
- Shannon R. Hinson, PhD,
- Brian G. Weinshenker, MD,
- Jay Mandrekar, PhD,
- John J. Chen, MD, PhD,
- Claudia F. Lucchinetti, MD,
- Yujuan Jiao, MD,
- Jessica Segan, MA,
- John E. Schmeling,
- John Mills, PhD,
- Eoin P. Flanagan, MBBCh,
- Andrew McKeon, MD and
- Sean J. Pittock, MD
- Jiraporn Jitprapaikulsan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James P. Fryer, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Masoud Majed, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carin Y. Smith, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah M. Jenkins, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philippe Cabre, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shannon R. Hinson, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brian G. Weinshenker, MD,
NONE
NONE
NONE
1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation
1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.,Oxford University,MVZ Labor PD Dr. Volkmann und Kollegen GbR, Hospices Civil de Lyon
NONE
NONE
1. Chugai: consulting regarding interpretation of neuromyelitis optica clinical trial 2. Mitsubishi Tanabe: consulting regarding design of neuromyelitis optica clinical trial
NONE
(1)VielaBio Pharmaceuticals, Adjudication Committee Member (2)Alexion Pharmaceuticals, Adjudication Committee Member
NONE
NONE
NONE
NONE
Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-08/2017
NONE
NONE
NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd., Oxford University, MVZ Labor PD Dr. Volkmann und Kollegen GbR and Hospices Civil de Lyon
NONE
NONE
NONE
- Jay Mandrekar, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John J. Chen, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research to Prevent Blindness, Inc., New York, NY.
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia F. Lucchinetti, MD,
(1)Member NIH/NINDS CNBT Study Section (2)Board of Trustee Member, Mayo Clinic (3)Board of Governor; Member, Mayo Clinic (4)Board of Directors, American Neurological Association (5)Director, American Neurological Association (ANA) Board of Directors
NONE
NONE
Brain Pathology, Guest Editor, NMO Symposium 2014
(1) patent re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica
(1)Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010)
NONE
Biogen Idec, travel reimbursement only
NONE
NONE
NONE
(1)Amendment 3: A Synchrotron X-ray Fluorescence Based Approach to Examine the Role of Metals in Multiple Sclerosis Tissues. Biogen Idec. 2)Tissue Pathogenesis of Progression in Multiple Sclerosis. Mayo Clinic Development
(1) The role of microglia in neuromyelitis optica. NIH R01NS 110949-1. Role: Co-Investigator. 09/01/2019- 08/31/2024 (2)Diagnosis of indeterminate brain lesions using MRI- based machine learning and polygenic risk models. National Institute of Neurological Disorders and Stroke NS 113803. Role: Co-Investigator. 09/01/2019-08/31/2024 (3)Myelin oligodendrocyte glycoprotein antibody disease: incidence, prevalence, outcome prediction and immunopathology. National Institute of Neurological Disorders and Stroke R01NS 113828-1. Role: Co- Investigator. 09/01/2019-08/31/2024
NONE
(1) National Multiple Sclerosis Society: 07/01/2016 - 06/30/2021 (2)FTIR and XRF Microscopy of MS Lesions. Kingsland Foundation. 07/01/2016-06/30/2021
NONE
NONE
(1) aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica;
NONE
NONE
NONE
- Yujuan Jiao, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jessica Segan, MA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John E. Schmeling,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John Mills, PhD,
NONE
NONE
NONE
NONE
Mass spectrometric measurement of monoclonal immunoglobulins for diagnosis monoclonal gammopathies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Mass spectrometric measurement of monoclonal immunoglobulins, Technology licensing to The Binding Site company, 2017.
NONE
NONE
NONE
NONE
- Eoin P. Flanagan, MBBCh,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am currently a site primary investigator in a randomized clinical trial on Medi551 in neuromyelitis optica spectrum disorder run by Medimmune. I receive compensation for time related to that activity.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew McKeon, MD and
NONE
NONE
NONE
I am a member of the editorial board of Neurology: Neuroimmunology and Neuroinflammation
Patent applications pending: Septin 5, Septin 7, GFAP, PDE10A, Kelch-11 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
NONE
NONE
NONE
NONE
Medimmune, Inc Euroimmun Grifols Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sean J. Pittock, MD
Alexion Pharmaceutical Advisory Board Medimmune/Viele Bio Advisory Board UCB pharmaceuticals Astellas
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and AEA (Autoimmune Encephalitis Associations).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (J.J., M.M., B.G.W., C.F.L., Y.J., E.P.F., A.M., S.J.P.), Laboratory Medicine and Pathology (J.J., J.P.F., S.R.H., J.E.S., J. Mills, A.M., S.J.P.), Health Sciences Research (C.Y.S., S.M.J., J. Mandrekar), Mayo Clinic, Rochester, MN; Department of Neurology (P.C.), Fort-de-France University Hospital Center, Pierre Zobda Quitman Hospital, Martinique; Center for MS and Autoimmune Neurology (B.G.W., J.J.C., C.F.L., J. S., J. Mills, E.P.F., A.M., S.J.P.), and Department of Ophthalmology (J.J.C.), Mayo Clinic, Rochester, MN.
- Correspondence
Dr. Pittock pittock.sean{at}mayo.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Alert Me
Recommended articles
-
Article
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L. Bennett, Ho Jin Kim et al.Neurology: Neuroimmunology & Neuroinflammation, March 26, 2021 -
Research Article
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum DisorderTetsuya Akaishi, Toshiyuki Takahashi, Tatsuro Misu et al.Neurology, May 12, 2021 -
Article
Neuromyelitis optica spectrum disordersComparison according to the phenotype and serostatusMaria Sepúlveda, Thaís Armangué, Nuria Sola-Valls et al.Neurology - Neuroimmunology Neuroinflammation, April 14, 2016 -
Article
Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMOJoanna Kitley, Mark Woodhall, M. Isabel Leite et al.Neurology - Neuroimmunology Neuroinflammation, June 18, 2015